Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 11,591 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: CHRONIC DISEASE Clear all

Conditions: Chronic Pancreatitis, Chronic Pain
Interventions: Quantitative Sensory Test 1, Quantitative Sensory Test 2, Quantitative Sensory Test 3; Diagnostic Test
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Pittsburgh, Pennsylvania

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
Interventions: Riliprubart, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 28
States / cities: Homewood, Alabama • Los Angeles, California • Orange, California + 24 more

Conditions: Coronary Artery Disease, Chronic Total Occlusion of Coronary Artery, Percutaneous Coronary Intervention
Interventions: Robotic CTO PCI, Conventional (Manual) CTO PCI; Device · Procedure
Lead sponsor: Siemens Healthineers Endovascular Robotics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Kansas City, Missouri • York, Pennsylvania • Seattle, Washington

Conditions: Staphylococcus Aureus
Interventions: AZD7760, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 242 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 40
States / cities: Huntsville, Alabama • Chula Vista, California • Glendale, California + 35 more

Conditions: Lymphoma
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: HIV-1 Infection, HIV Infections
Interventions: mRNA-transfected autologous dendritic cells, autologous dendritic cells with no mRNA transfection; Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C Viral Infection, Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1
Interventions: Faldaprevir, TD-6450, Ribavirin; Drug
Lead sponsor: Trek Therapeutics, PBC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Coronado, California • Bradenton, Florida • Germantown, Tennessee

Conditions: Palliative Care, Chronic Disease
Interventions: Reiki; Other
Lead sponsor: Ohio State University; Other
Eligibility: 10 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Akron, Ohio • Columbus, Ohio

Conditions: Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Interventions: tafasitamab, parsaclisib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 6 more

Conditions: Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: sargramostim, amifostine trihydrate, carboplatin, cyclophosphamide; Biological · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pulmonary Sarcoidosis
Interventions: PD 0360324, Normal Saline for injection; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 5
States / cities: New York, New York • Cincinnati, Ohio

Conditions: Burn, Chronic Pain Following Thermal Burn Injury, Non-Pharmacological Interventions, Virtual Reality, Sleep Disturbance, Anxiety, Depressive Symptoms, Fatigue Symptom, Pruritus, Burn Injury, Progressive Muscle Relaxation
Interventions: Virtual Reality-Enhanced Progressive Muscle Relaxation, Standard Progressive Muscle Relaxation; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Asthma, COPD, Cystic Fibrosis, Ciliary Motility Disorders, Bronchiectasis, Airway Malacia, Healthy Control
Interventions: AWARE; Diagnostic Test
Lead sponsor: Indiana University; Other
Eligibility: 8 Years to 70 Years
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Indianapolis, Indiana • Pittsburgh, Pennsylvania

Conditions: Diabetic Foot Ulcer (DFU), Amnio-Maxx
Interventions: Amnio-Maxx® Dual Layer Amnion Patch, Standard of Care (Investigator Choice); Biological · Other
Lead sponsor: Royal Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: Burbank, California • Miami, Florida • Stone Mountain, Georgia + 5 more

Conditions: Hypertension, Renal Failure Chronic Requiring Hemodialysis, Blood Pressure, Dialysis
Interventions: Antihypertensive Agents, Dry weight Challenge, Extend dialysis treatment time and re-challenge estimated dry weight; Drug · Other · Dietary Supplement
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 21
States / cities: Boston, Massachusetts • Concord, Massachusetts • Jamaica Plain, Massachusetts + 9 more

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: SAR445088 (IV), SAR445088 (SC); Drug
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Fairway, Kansas + 2 more

Conditions: Rhinovirus Infection
Interventions: VPV 1000 mg, VPV 500 mg, Placebo; Drug · Other
Lead sponsor: Altesa Biosciences, Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 37
States / cities: Mobile, Alabama • Tempe, Arizona • Inglewood, California + 33 more

Conditions: Nasal Polyps
Interventions: GSK5784283, Placebo, Standard of Care; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Sherman Oaks, California • Greenville, South Carolina • Plano, Texas

Conditions: Otitis Media With Effusion, Food Hypersensitivity
Interventions: Food Allergy Testing, Adenoidectomy, BMT; Other · Procedure
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: Up to 4 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Hepatitis C
Interventions: XTL 6865; Drug
Lead sponsor: XTL Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 4
States / cities: Indianapolis, Indiana • New York, New York • Chapel Hill, North Carolina + 1 more

Conditions: Leukemia, Lymphocytic, Chronic, Lymphoma, Small Lymphocytic
Interventions: Rituximab, Beta-Glucan; Drug · Dietary Supplement
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Chronic Kidney Disease
Interventions: Zibotentan (Treatment A), Dapagliflozin (Treatment A), Zibotentan/Dapagliflozin - Formulation 1 (Treatment B), Zibotentan/Dapagliflozin - Formulation 2 (Treatment C); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Chronic Myeloid Leukemia
Interventions: ponatinib, imatinib (Gleevec/ Glivec); Drug
Lead sponsor: Ariad Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 67
States / cities: Burbank, California • Los Angeles, California • Pleasant Hill, California + 53 more

Conditions: Heart Failure, Congestive, Pulmonary Disease, Chronic Obstructive, Depression, Anxiety
Interventions: ACCES - Adjusting to Chronic Conditions with Education and Support; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Pancreatic Quantitative Sensory Testing (P-QST) to Predict Treatment Response for Pain in Chronic Pancreatitis

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

Cardiac Cath Lab Staff Radiation Exposure

A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant

A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects

A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection

Teaching Parents Reiki for Their Adolescents Receiving Palliative Care

A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer

A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis

VR-PMR for Post-Burn Symptoms

Acoustic Waveform Respiratory Evaluation

Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.

Blood Pressure in Dialysis Patients

Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD

A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Food Allergy - Tubes - Adenoids (FATA) Trial

Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection

Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)

Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Transforming Psychotherapy for Chronically Ill Patients